Anti-parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists

Arcuri, Ludovico, Novello, Salvatore, Frassineti, Martina, Mercatelli, Daniela, Pisano, Clarissa Anna, Morella, Ilaria ORCID: https://orcid.org/0000-0001-5691-5400, Fasano, Stefania ORCID: https://orcid.org/0000-0002-3696-7139, Journigan, Blair V., Meyer, Michael E., Polgar, Willma E., Brambilla, Riccardo ORCID: https://orcid.org/0000-0003-3569-5706, Zaveri, Nurulain T. and Morari, Michele 2018. Anti-parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. British Journal of Pharmacology 175 (5) , pp. 782-796. 10.1111/bph.14123

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

Background and Purpose We previously showed that nociceptin/orphanin FQ opioid peptide (NOP) receptor agonists attenuate the expression of levodopa-induced dyskinesia in animal models of Parkinson's disease. We now investigate the efficacy of two novel, potent and chemically distinct NOP receptor agonists, AT-390 and AT-403, to improve Parkinsonian disabilities and attenuate dyskinesia development and expression. Experimental Approach Binding affinity and functional efficacy of AT-390 and AT-403 at the opioid receptors were determined in radioligand displacement assays and in GTPγS binding assays respectively, conducted in CHO cells. Their anti-Parkinsonian activity was evaluated in 6-hydroxydopamine hemi-lesioned rats whereas the anti-dyskinetic properties were assessed in 6-hydroxydopamine hemi-lesioned rats chronically treated with levodopa. The ability of AT-403 to inhibit the D1 receptor-induced phosphorylation of striatal ERK was investigated. Key Results AT-390 and AT-403 selectively improved akinesia at low doses and disrupted global motor activity at higher doses. AT-403 palliated dyskinesia expression without causing sedation in a narrow therapeutic window, whereas AT-390 delayed the appearance of abnormal involuntary movements and increased their duration at doses causing sedation. AT-403 did not prevent the priming to levodopa, although it significantly inhibited dyskinesia on the first day of administration. AT-403 reduced the ERK phosphorylation induced by SKF38393 in vitro and by levodopa in vivo. Conclusions and Implications NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation. The therapeutic window, however, varies across compounds. AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Neuroscience and Mental Health Research Institute (NMHRI) Biosciences
Publisher:	Wiley: 12 months
ISSN:	0007-1188
Date of First Compliant Deposit:	28 November 2017
Date of Acceptance:	26 November 2017
Last Modified:	11 Apr 2024 16:24
URI:	https://orca.cardiff.ac.uk/id/eprint/107118

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item